Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SPAM GARBAGE. REPORT IT FOR BEING DISRUPTIVE.
Posted this garbage on 91 different boards!!
https://www.lse.co.uk/profiles/jilen/
I sold my shares earlier this the year because Im getting a far better div return on other stocks, GSK is currently only paying 3.44%. as of today rate.
I def intend to return later in the year if the div improves
Glaxo. Here is an extract from their 4th Quarter statement in late January this year :-
"The Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p(3) per share).
Dividends remain an essential component of total shareholder return and GSK recognises the importance of
dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive
dividend policy will be implemented guided by a 40 to 60 percent pay-out ratio through the investment cycle.
Consistent with this, and reflecting strong business performance during the year, GSK now expects to declare an
increased dividend of 16.00p for Q4 2023 and 58.00p per share for full year 2023. The expected dividend for 2024 is
60.00p. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment
strategy for growth alongside the sustainability of the dividend."
I personally think they will modestly exceed the 60p divided forecast for this year.
Haleon hav a policy of rising divi. Anyone know what gsk policy is, and ifit seems to be gently rising since the split, and likely to rise in future.. opinion only of course.
Why do they get picked on by NHS giving Salamol to asthma sufferers saying CFC free! Ventoline a long proven Glaxo medication with a good effective propellant that the feeble replacement does not have!
Tricky/old news, they are moving to Earnshaw St at the top of Oxford St
I can’t remember the last bad news here.
The Blenrep phase 3 DREAMM-8 trial met its primary endpoint of progression free survival with the regimen shown to significantly extend the time to disease progression or death versus the existing standard of care. The dataset has been unblinded early on the advice of its independent data monitoring committee. The readout comes just one month after GSK announced positive results from the DREAMM-7 trial. Armed with successes on two phase 3 trials GSK will be in discussion with the FDA about the reintroduction of the drug in the US.
Analysts at Citi anticipate risk adjusted Blenrep sales of £2.5bn in 2035.
No wonder GSK shares are up over 18% since the beginning of the year.
I'm hovering on the sell button TBH. Similar buy in average but need to shift a stack before an imminent mortgage renewal rate increase and the CGT reduction. A bird in the hand and all that.....
End of Tax year 23-24 on 05.04.24
HMRC are to reduce Capital Gains Tax allowance.
Why not rethink!!!
To break a blank posting day, when Glaxo has made a nice move up beyond £17 - gone well since my last purchase at £14 - have a below £13 average - not yet a high enough valuation to contemplate any sales.
GSK has sold GSK House in Brentford to Hadley Property Group.
Good news OR 'not'
I bought in at 13.28
More to go.
https://www.gsk.ai/
This should not have a negative impact on the SP in any way. GSK had the same results in the 2nd year. This was all about being first to Market which GSK was. People don’t like changing medication once something works for them. It’s then all about building on this by gaining approval for younger ages which GSK is also well ahead of the competition on.
It probably has to do with Pfizer's announcement from yesterday, threatening GSK's dominance so far here.
Pfizer says its RSV shot is protective through a second year
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-its-rsv-shot-is-protective-through-second-year-2024-02-29/
Since you ask, Badgernator, I have only kept a small part, reinvesting some in Puretech Health (Doubling this holding) and diversifying into 'safe' emerging fund Utilico Emerging Markets. All the best!
It's slowly drifting down and struggles to pass £17 resistance. I mean, is it really the Zantac case to hold this share down? historical defensive stock, solid company, good results, fairly decent dividend ...it should hoovering around £20 at least :-(
Good luck olda couldn’t hold for the 1750 eh? I obviously think selling was a mistake as I still hold. Any plans for the money? I’m hoping gsk has the wind in its sails now. I’m hoping they they know what they are doing settling these cases. Once the Zantac litigation is over I can’t see what will hold this back from getting the same rating as it’s peers.
....close to £17 and I think ex-div. Small profit but releases a lot of cash. Good luck to all who hang on.
According to that, it could also go down. I have come to expect GSK to do both.
9.23% since 4th January 2024. Appears to be plenty more to come.
"The 20 analysts offering 12 month price targets for GSK plc have a median target of 1,770.00, with a high estimate of 2,490.00 and a low estimate of 1,200.00. The median estimate represents a 5.84% increase from the last price of 1,672.40."
GSK reports positive results from gonorrhoea treatment trial.
GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.
https://www.investments.halifax.co.uk/research-centre/news-centre/article/?id=16312944&type=bsm
Ripley94, ref. Barnes-IBMer-Billionaires? Hold on to CNA, GSK & HLN?
Citi are not one of my favorite institutions, but for once it is nice to see a little reasoning behind a change in view rather than arbitrary cuts & raises as with LGEN last week.
Still difficult to monetize the reasoning though - so as ever taken with a large pinch of salt.
Citi upgrade is based not only on Blenrep’s under appreciated revenue potential of £2.5bn peak year sales but also the Zantac liability outlook RSV/Shingrix astute business development, increasingly positive ViiV outlook and GSK’s recent commercial and pipeline wins. As well as upgrading its rating from neutral to buy Citi upped its price target to 2100p from 1700p.